Even though it was suggested that neutralizing secreted Sparcl1 with antibodies may be beneficial for reducing acute and chronic pain,22 this is not a good strategy for treating CIPN in TNBC patients as data from the TCGA PanCancer Atlas indicate that high Sparcl1 mRNA expression correlates with better survival (https://www.proteinatlas.org/ENSG00000152583‐Sparcl1/pathology/breast+cancer). This evidence concerns the gene SPARCL1 and cancer.